Ziopharm Oncology company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

ziopharm.com

Founded Year

2003

Stage

PIPE - II | IPO

Market Cap

0.10B

Stock Price

0.50

About Ziopharm Oncology

ZIOPHARM is a biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of in-licensed cancer drugs to address unmet medical needs. The Company applies new insights from molecular and cancer biology to understand the efficacy and safety limitations of approved and developmental cancer therapies and identifies proprietary and related molecules for better patient treatment.

Ziopharm Oncology Headquarter Location

One First Avenue Parris Building, #34, Navy Yard Plaza

Boston, Massachusetts, 02129,

United States

+1 617 259 1970

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Ziopharm Oncology

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Ziopharm Oncology is included in 1 Expert Collection, including Cancer.

C

Cancer

4,784 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

Ziopharm Oncology Patents

Ziopharm Oncology has filed 11 patents.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

11/14/2012

10/21/2014

Transcription factors, Antineoplastic drugs, Sesquioxides, Oncology, Experimental cancer drugs

Grant

Application Date

11/14/2012

Grant Date

10/21/2014

Title

Related Topics

Transcription factors, Antineoplastic drugs, Sesquioxides, Oncology, Experimental cancer drugs

Status

Grant

Latest Ziopharm Oncology News

11:42 EDT CARsgen Appoints Dr. Raffaele Baffa as Chief Medical Officer

Apr 7, 2022

News provided by Share this article Share this article SHANGHAI and BOSTON, April 7, 2022 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T cell therapies for the treatment of hematologic malignancies and solid tumors, announces that Dr. Raffaele Baffa ("Dr. Baffa") has been appointed as the Chief Medical Officer ("CMO") of the Company, responsible for overseeing the global clinical development strategies and operations for the Company's innovative pipeline product candidates. Dr. Baffa will report to Dr. Zonghai Li, Founder, Chairman of the Board, CEO, CSO of CARsgen Therapeutics Holdings Limited. Dr. Raffaele Baffa, Chief Medical Officer, CARsgen Therapeutics Holdings Limited Dr. Baffa has rich experiences in pharmaceutical industry and research institutes, taking various leadership positions in multi-national corporations and biotech companies. Prior to joining CARsgen, Dr. Baffa served as Chief Medical Officer and Executive Vice President of Research & Development at Ziopharm Oncology (NASDAQ: ZIOP ), which was rebranded to Alaunos in January 2022. (NASDAQ: TCRT ). Prior to Ziopharm Oncology, Dr. Baffa was Head of Research & Development and Chief Medical Officer in Medisix Therapeutics, a company focused on developing novel immune cell therapies. Dr. Baffa was the Vice President, Therapeutic Area Head of Oncology, Global Clinical Development of Shire Pharmaceuticals, and following the acquisition of the oncology division by Servier Pharmaceuticals, Dr. Baffa served as the Chief Medical Officier of Servier Pharmaceuticals. Dr. Baffa has also held leadership positions at well-known pharmaceutical companies, such as Pfizer and Sanofi. Dr. Baffa earned an M.D. from University of Padova, School of Medicine and a Ph.D. in biology and molecular pathology from University of Parma in Italy. Dr. Zonghai Li, Founder, Chairman of the Board, Chief Executive Officer, and Chief Scientific Officer of CARsgen Therapeutics Holdings Limited, said, "We warmly welcome Dr. Baffa to join CARsgen. Dr. Baffa is a medical professional and industry veteran with extensive experiences in clinical development and translational sciences in the field of oncology and cellular immunotherapy. Dr. Baffa brings a wealth of clinical, medical, and leadership experiences from multinational corporations and biotechnology companies. Dr. Baffa joins us at an exciting time as the clinical trials for both CT053 and CT041 are progressing in North America and being explored in other territories. Dr. Baffa's joining will further accelerate the global clinical development of our innovative product candidates." Dr. Raffaele Baffa, Chief Medical Officer of CARsgen Therapeutics Holdings Limited, said, "I am very excited to join CARsgen. As one of the leading companies in cell therapies globally, CARsgen has developed a rich and differentiated product pipeline and a suite of exciting technology platforms such as THANK-uCAR® for allogeneic CAR T and LADAR® for precise targeting. CARsgen has also shown big ambitions with continuous investment for the global market, such as the establishment of the manufacturing facility in the United States. I look forward to working closely with colleagues in CARsgen and external partners to accelerate CARsgen's global clinical development and bring more innovative products to cancer patients." About CARsgen Therapeutics Holdings Limited CARsgen is a biopharmaceutical company with operations in China and the U.S. and is focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors. The Company has built an integrated cell therapy platform with in-house capabilities that span target discovery, antibody development, clinical trials, and commercial-scale manufacturing. CARsgen has internally developed novel technologies and a product pipeline with global rights to address major challenges of CAR T-cell therapies, such as improving the safety profile, enhancing the efficacy in treating solid tumors, and reducing treatment costs. The Company's vision is to become a global biopharmaceutical leader that brings innovative and differentiated cell therapies to cancer patients worldwide and makes cancer curable. SOURCE CARsgen Therapeutics

Ziopharm Oncology Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Ziopharm Oncology Rank

  • When was Ziopharm Oncology founded?

    Ziopharm Oncology was founded in 2003.

  • Where is Ziopharm Oncology's headquarters?

    Ziopharm Oncology's headquarters is located at One First Avenue, Boston.

  • What is Ziopharm Oncology's latest funding round?

    Ziopharm Oncology's latest funding round is PIPE - II.

  • Who are Ziopharm Oncology's competitors?

    Competitors of Ziopharm Oncology include Gelesis, Tizona Therapeutics, MOgene LC, Celator Pharmaceuticals, Jennerex Biotherapeutics, Telormedix, aFraxis, Merrimack Pharmaceuticals, Cellectar Biosciences, HealOr and 13 more.

You May Also Like

P
Pivotal Biosciences

Pivotal BioSciences, Inc. is a company focused on the development and commercialization of cancer therapies.

B
BioMarck Pharmaceuticals

BioMarck Pharmaceuticals is a biopharmaceutical company dedicated to the discovery and development of drugs for the treatment of pulmonary diseases and disorders associated with the over-secretion of mucus and pulmonary inflammation. In developing its lead compound, BIO-11006 Inhalation Solution, BioMarck has chosen chronic obstructive pulmonary disease (specifically chronic bronchitis) as its first target, but other diseases including asthma, and cystic fibrosis are later disease targets. BIO-11006 Inhalation Solution works by a novel dual mechanism; it inhibits both the secretion of mucus in the lungs and pulmonary inflammation. These aspects of BIO-11006 Inhalation Solution have been demonstrated in several different animal models. In addition, BioMarck has completed a full panel of preclinical safety studies, has an active IND with the FDA, has completed two BIO-11006 in Phase 1 clinical studies, and is currently conducting a Phase 2 study of the efficacy of BIO-11006 in COPD patients.

Immunservice Logo
Immunservice

Immunservice is a biopharmaceutical company addressing orphan disease indications as well as large market indication areas, especially those of high unmet medical need.Immunservice's biomimetic approach translates human immune hormones into well tolerated and highly effective marketable drugs that improve survival and quality of life in patients.Biomimetic therapy has the clear potential to cure patients with cancer, even those who are in urgent need and have little or no treatment alternatives.

A
American Stem Cell

ASC is a privately held biotechnology company dedicated to the development and commercialization of enabling technologies to enhance and expand the therapeutic potential of stem cell therapies. The key technology platforms (ASC-101 and ASC-201) are designed to improve the homing and engraftment of stem cells to target organs and increase their therapeutic potential for cancer patients. Additionally, these platforms have the potential to enhance stem cell treatment of inflammation from chemotherapy/radiation, solid tumors, autoimmune diseases, and ischemic diseases including myocardial infarction and stroke. ASC has strategic partnerships with medical research institutions including the University of Texas M.D. Anderson Cancer Center, the Oklahoma Medical Research Foundation, University of California, the Burnham Institute, Indiana University, Rush Presbyterian and VidaCord Technologia Biomedica.

A
Anaborex

Anaborex Anaborex is an early stage biotechnology company developing drugs for the treatment of the wasting syndrome many cancer patients experience towards the late stages of their disease.

C
Can-Fite Biopharma

Can-Fite is an Israeli science-based biopharmaceutical company with the mission to develop treatments for autoimmune diseases and cancer. The company's drugs which piggyback on a natural mechanism, are small molecules, orally administered, induce specific activity towards their target pathological cells and demonstrated an excellent safety profile in human clinical studies.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.